-DOCSTART- -X- O
Hepatitis -X- _ O
C -X- _ O
virus -X- _ O
( -X- _ O
HCV -X- _ O
) -X- _ O
is -X- _ O
a -X- _ O
blood-borne -X- _ O
pathogen -X- _ O
causing -X- _ O
acute -X- _ O
and -X- _ O
chronic -X- _ O
hepatitis. -X- _ O
A -X- _ O
significant -X- _ O
number -X- _ O
of -X- _ O
people -X- _ O
chronically -X- _ O
infected -X- _ O
with -X- _ O
HCV -X- _ O
develop -X- _ O
cirrhosis -X- _ O
and -X- _ O
/ -X- _ O
or -X- _ O
liver -X- _ O
cancer. -X- _ O
The -X- _ O
pathophysiologic -X- _ O
mechanisms -X- _ O
of -X- _ O
hepatocyte -X- _ O
damage -X- _ O
associated -X- _ O
with -X- _ O
chronic -X- _ O
HCV -X- _ O
infection -X- _ O
are -X- _ O
not -X- _ O
fully -X- _ O
understood -X- _ O
yet -X- _ O
, -X- _ O
mainly -X- _ O
due -X- _ O
to -X- _ O
the -X- _ O
lack -X- _ O
of -X- _ O
an -X- _ O
in -X- _ O
vitro -X- _ O
system -X- _ O
able -X- _ O
to -X- _ O
recapitulate -X- _ O
the -X- _ O
stages -X- _ O
of -X- _ O
infection -X- _ O
in -X- _ O
vivo. -X- _ O
Several -X- _ O
studies -X- _ O
underline -X- _ O
that -X- _ O
HCV -X- _ O
virus -X- _ O
replication -X- _ O
depends -X- _ O
on -X- _ O
redox-sensitive -X- _ O
cellular -X- _ O
pathways -X- _ O
; -X- _ O
in -X- _ O
addition -X- _ O
, -X- _ O
it -X- _ O
is -X- _ O
known -X- _ O
that -X- _ O
virus -X- _ O
itself -X- _ O
induces -X- _ O
alterations -X- _ O
of -X- _ O
the -X- _ O
cellular -X- _ O
redox -X- _ O
state. -X- _ O
However -X- _ O
, -X- _ O
the -X- _ O
exact -X- _ O
interplay -X- _ O
between -X- _ O
HCV -X- _ O
replication -X- _ O
and -X- _ O
oxidative -X- _ O
stress -X- _ O
has -X- _ O
not -X- _ O
been -X- _ O
elucidated. -X- _ O
In -X- _ O
particular -X- _ O
, -X- _ O
the -X- _ O
role -X- _ O
of -X- _ O
reduced -X- _ O
glutathione -X- _ O
( -X- _ O
GSH -X- _ O
) -X- _ O
in -X- _ O
HCV -X- _ O
replication -X- _ O
and -X- _ O
infection -X- _ O
is -X- _ O
still -X- _ O
not -X- _ O
clear. -X- _ O
We -X- _ O
set -X- _ O
up -X- _ O
an -X- _ O
in -X- _ O
vitro -X- _ O
system -X- _ O
, -X- _ O
based -X- _ O
on -X- _ O
low -X- _ O
m.o.i. -X- _ O
of -X- _ O
Huh7.5 -X- _ B-Patient
cell -X- _ I-Patient
line -X- _ I-Patient
with -X- _ O
a -X- _ O
HCV -X- _ B-Intervention
infectious -X- _ I-Intervention
clone -X- _ I-Intervention
( -X- _ I-Intervention
J6 -X- _ I-Intervention
/ -X- _ I-Intervention
JFH1 -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ O
that -X- _ O
reproduced -X- _ O
the -X- _ O
acute -X- _ O
and -X- _ O
persistent -X- _ O
phases -X- _ O
of -X- _ O
HCV -X- _ O
infection -X- _ O
up -X- _ O
to -X- _ O
76 -X- _ O
days -X- _ O
of -X- _ O
culture. -X- _ O
We -X- _ O
demonstrated -X- _ O
that -X- _ O
the -X- _ O
acute -X- _ B-Outcome
phase -X- _ I-Outcome
of -X- _ I-Outcome
HCV -X- _ I-Outcome
infection -X- _ I-Outcome
is -X- _ I-Outcome
characterized -X- _ I-Outcome
by -X- _ I-Outcome
the -X- _ I-Outcome
elevated -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
reactive -X- _ I-Outcome
oxygen -X- _ I-Outcome
species -X- _ I-Outcome
( -X- _ I-Outcome
ROS -X- _ I-Outcome
) -X- _ I-Outcome
associated -X- _ I-Outcome
in -X- _ I-Outcome
part -X- _ I-Outcome
with -X- _ I-Outcome
an -X- _ I-Outcome
increase -X- _ I-Outcome
of -X- _ I-Outcome
NADPH-oxidase -X- _ I-Outcome
transcripts -X- _ I-Outcome
and -X- _ I-Outcome
activity -X- _ I-Outcome
and -X- _ I-Outcome
a -X- _ I-Outcome
depletion -X- _ I-Outcome
of -X- _ I-Outcome
GSH -X- _ I-Outcome
accompanied -X- _ I-Outcome
by -X- _ I-Outcome
high -X- _ I-Outcome
rates -X- _ I-Outcome
of -X- _ I-Outcome
viral -X- _ I-Outcome
replication -X- _ I-Outcome
and -X- _ I-Outcome
apoptotic -X- _ I-Outcome
cell -X- _ I-Outcome
death. -X- _ I-Outcome
Conversely -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
chronic -X- _ I-Outcome
phase -X- _ I-Outcome
is -X- _ I-Outcome
characterized -X- _ I-Outcome
by -X- _ I-Outcome
a -X- _ I-Outcome
reestablishment -X- _ I-Outcome
of -X- _ I-Outcome
reduced -X- _ I-Outcome
environment -X- _ I-Outcome
due -X- _ I-Outcome
to -X- _ I-Outcome
a -X- _ I-Outcome
decreased -X- _ I-Outcome
ROS -X- _ I-Outcome
production -X- _ I-Outcome
and -X- _ I-Outcome
increased -X- _ I-Outcome
GSH -X- _ I-Outcome
content -X- _ I-Outcome
in -X- _ I-Outcome
infected -X- _ I-Outcome
cells -X- _ I-Outcome
that -X- _ I-Outcome
might -X- _ I-Outcome
concur -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
establishment -X- _ I-Outcome
of -X- _ I-Outcome
viral -X- _ I-Outcome
persistence. -X- _ I-Outcome
Treatment -X- _ O
with -X- _ O
the -X- _ O
prooxidant -X- _ O
auranofin -X- _ O
of -X- _ O
the -X- _ O
persistently -X- _ O
infected -X- _ O
cultures -X- _ O
induced -X- _ O
the -X- _ O
increase -X- _ O
of -X- _ O
viral -X- _ O
RNA -X- _ O
titer -X- _ O
, -X- _ O
suggesting -X- _ O
that -X- _ O
a -X- _ O
prooxidant -X- _ O
state -X- _ O
could -X- _ O
favor -X- _ O
the -X- _ O
reactivation -X- _ O
of -X- _ O
HCV -X- _ O
viral -X- _ O
replication -X- _ O
that -X- _ O
in -X- _ O
turn -X- _ O
caused -X- _ O
cell -X- _ O
damage -X- _ O
and -X- _ O
death. -X- _ O
Our -X- _ O
results -X- _ O
suggest -X- _ O
that -X- _ O
targeting -X- _ O
the -X- _ O
redox-sensitive -X- _ O
host-cells -X- _ O
pathways -X- _ O
essential -X- _ O
for -X- _ O
viral -X- _ O
replication -X- _ O
and -X- _ O
/ -X- _ O
or -X- _ O
persistence -X- _ O
may -X- _ O
represent -X- _ O
a -X- _ O
promising -X- _ O
option -X- _ O
for -X- _ O
contrasting -X- _ O
HCV -X- _ O
infection -X- _ O
. -X- _ O

